First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

This study compares two chemotherapy regimens — mCapOX and mFOLFOX6, both combined with cetuximab — as first-line treatment for metastatic colorectal cancer (cancer that has spread) on the left side of the colon, in patients whose tumors do not have RAS or BRAF mutations. **You may be eligible if...** - You are 18 or older - You have confirmed metastatic colorectal cancer (adenocarcinoma) starting on the left side of the colon - Your tumor tests negative for RAS and BRAF mutations - You have measurable disease on scans - You have not had prior chemotherapy or targeted therapy for metastatic disease - Your physical health is good (ECOG performance score 0–1) **You may NOT be eligible if...** - Your tumor has RAS or BRAF mutations - You have previously received chemotherapy or targeted therapy for metastatic disease (prior adjuvant therapy that ended more than 12 months ago may be acceptable) - You have active infections, severe heart problems, or other significant medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.